Targeting a therapeutic LIF transgene to muscle via the immune system ameliorates muscular dystrophy
A number of therapeutic agents aimed at reducing pathology in Duchenne muscular dystrophy have been developed, but may have off-target effects when delivered systemically. Here, the authors express the therapeutic LIF transgene in leukocytes, and show this results in targeting to inflamed dystrophic...
Guardado en:
Autores principales: | Steven S. Welc, Ivan Flores, Michelle Wehling-Henricks, Julian Ramos, Ying Wang, Carmen Bertoni, James G. Tidball |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/264ed254b4494b4a8400489886319488 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
NAD+ biosynthesis ameliorates a zebrafish model of muscular dystrophy.
por: Michelle F Goody, et al.
Publicado: (2012) -
MiR-199-3p enhances muscle regeneration and ameliorates aged muscle and muscular dystrophy
por: Masashi Fukuoka, et al.
Publicado: (2021) -
Silencing Nfix rescues muscular dystrophy by delaying muscle regeneration
por: Giuliana Rossi, et al.
Publicado: (2017) -
Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy
por: Niclas E. Bengtsson, et al.
Publicado: (2017) -
FKRP-dependent glycosylation of fibronectin regulates muscle pathology in muscular dystrophy
por: A. J. Wood, et al.
Publicado: (2021)